Published in World J Gastrointest Pharmacol Ther on November 06, 2016
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
Shared principles in NF-kappaB signaling. Cell (2008) 20.96
Unravelling the pathogenesis of inflammatory bowel disease. Nature (2007) 18.52
The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol (2009) 13.87
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science (1995) 11.16
Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science (2000) 10.98
Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol (2008) 5.18
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2006) 3.32
Cytokines in inflammatory bowel disease. Nat Rev Immunol (2014) 3.24
A20: central gatekeeper in inflammation and immunity. J Biol Chem (2008) 2.83
The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol (2009) 2.74
Tumour necrosis factor and Crohn's disease. Gut (1997) 2.27
NF-kappaB in inflammatory bowel disease. J Intern Med (2008) 2.21
Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med (2010) 2.15
Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut (2005) 1.84
Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol (2011) 1.77
The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J Mol Med (Berl) (2008) 1.58
Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol (2010) 1.33
Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes. J Immunol (2009) 1.26
Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol (2008) 1.15
A20 inhibits toll-like receptor 2- and 4-mediated interleukin-8 synthesis in airway epithelial cells. Am J Respir Cell Mol Biol (2004) 1.13
A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol (2009) 1.12
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut (2014) 1.11
Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol (2006) 1.06
Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 1.02
A20 attenuates allergic airway inflammation in mice. J Immunol (2009) 0.98
Lipopolysaccharide: basic biochemistry, intracellular signaling, and physiological impacts in the gut. Intest Res (2014) 0.92
Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut (1999) 0.90
A20 expression in dendritic cells protects mice from LPS-induced mortality. Eur J Immunol (2014) 0.80
Roles of A20 in autoimmune diseases. Immunol Res (2016) 0.79
[Expression of zinc finger protein A20 in pediatric inflammatory bowel disease]. Zhonghua Er Ke Za Zhi (2011) 0.77